Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies. This is an ASCO Meeting ...
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers. Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results